miR-204 acts as a molecular switch inhibiting osteoblastic transdifferentiation of human aortic valve interstitial cells by targeting Runx2, highlighting a potential therapeutic target for aortic valve calcification.
Answers are grounded in this paper and cite their sources.
Supports miR-204 as target in aortic valve calcification; leaves open translation from animal models to humans.
Osteoblast differentiation of valve interstitial cells (VICs) is a key step in valve calcification, but the molecular mechanisms involved are not fully understood. In this study, we aimed to investigate whether microRNA (miR)-204-regulated VICs differentiation through modulation of runt-related transcription factor 2 (Runx2), a key transcription factor for osteogenesis. Our data demonstrated that miR-204 was markedly downregulated in both human calcified aortic valves and bone morphogenetic protein (BMP)-2-stimulated aortic VICs. In vitro experiments showed that miR-204 acted as a negative regulator of osteogenic differentiation by repressing Runx2 and thereby inhibiting expression of osteoblast-related genes, including alkaline phosphatase and osteocalcin, which were all induced by BMP-2. Luciferase reporter assays validated Runx2 as the direct target of miR-204. Furthermore, increased alkaline phosphatase activity and osteocalcin expression after miR-204 inhibition were abolished by small interfering RNA-mediated silencing of Runx2. Overall, these data suggested miR-204 as a possible molecular switch inhibiting osteoblastic transdifferentiation of human aortic VICs and targeting miR-204 may have therapeutic potential for human aortic valve calcification.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: